Daré Bioscience, Inc.
DARE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -99.7% | -71.9% | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -146,110.2% | -670.6% | -201.4% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -239,259.6% | -1,093.4% | -313.6% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -41,430.9% | -1,074.2% | -309.5% | – |
| EPS Diluted | -0.48 | -4.15 | -4.39 | -7.52 |
| % Growth | 88.4% | 5.5% | 41.6% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |